ABSTRACT
MAO-A catalyzes the oxidative degradation of monoamines and is thus implicated in sex-specific neuroplastic processes that influence gray matter (GM) density (GMD) and microstructure (GMM). Given the exact monitoring of plasma hormone levels and sex steroid intake, transgender individuals undergoing gender-affirming hormone therapy (GHT) represent a valuable cohort to potentially investigate sex steroid-induced changes of GM and concomitant MAO-A density. Here, we investigated the effects of GHT over a median time period of 4.5 months on GMD and GMM as well as MAO-A distribution volume. To this end, 20 cisgender women, 11 cisgender men, 20 transgender women and 10 transgender men underwent two MRI scans in a longitudinal design. PET scans using [11C]harmine were performed before each MRI session in a subset of 35 individuals. GM changes determined by diffusion weighted imaging (DWI) metrics for GMM and voxel based morphometry (VBM) for GMD were estimated using repeated measures ANOVA. Regions showing significant changes of both GMM and GMD were used for the subsequent analysis of MAO-A density. These involved the fusiform gyrus, rolandic operculum, inferior occipital cortex, middle and anterior cingulum, bilateral insula, cerebellum and the lingual gyrus (post-hoc tests: pFWE+Bonferroni < 0.025). In terms of MAO-A distribution volume, no significant effects were found. Additionally, the sexual desire inventory (SDI) was applied to assess GHT-induced changes in sexual desire, showing an increase of SDI scores among transgender men. Changes in the GMD of the bilateral insula showed a moderate correlation to SDI scores (rho = - 0.62, pBonferroni = 0.047). The present results are indicative of a reliable influence of gender-affirming hormone therapy on 1) GMD and GMM following an interregional pattern and 2) sexual desire specifically among transgender men.
Subject(s)
Gray Matter , Monoamine Oxidase , Positron-Emission Tomography , Transgender Persons , Humans , Gray Matter/drug effects , Gray Matter/diagnostic imaging , Male , Adult , Female , Monoamine Oxidase/blood , Monoamine Oxidase/metabolism , Young Adult , Brain/diagnostic imaging , Brain/drug effects , Magnetic Resonance Imaging , Middle Aged , Longitudinal StudiesABSTRACT
Exposure to tobacco smoke (ETS) is one of the main risk factors for cardiovascular disease (CVD). Renalase is a protein that may play a role in the pathogenesis of CVD. The aim of the study was to assess the relationship between ETS and serum renalase concentration. A group of 109 patients was recruited for this study (49.7 ± 14.7 years). In accordance with the questionnaire, patients were divided into the following subgroups: subgroup A- declaring themselves active smokers (n = 36), subgroup B- declaring themselves non-smokers and exposed to environmental tobacco smoke (n = 35), subgroup C- declaring themselves non-smokers and not exposed to environmental tobacco smoke (n = 38). The same patients were divided based on cotinine concentration into the following subgroups: subgroup D- active smokers (n = 42), subgroup E- non-smokers exposed to environmental tobacco smoke (n = 66), and subgroup F- non-smokers not exposed to environmental tobacco smoke (n = 1). Serum cotinine concentration and serum renalase concentration were measured using ELISA tests. Serum renalase concentration was statistically significantly higher in subgroup C than in subgroups A and B and in subgroup E and F than in D. There was a negative correlation between serum cotinine concentration and serum renalase concentration (r = -0.41, p < 0.05). Regression analysis showed that higher BMI, higher diastolic blood pressure, coronary artery disease and higher serum cotinine concentration are independent risk factors of lower serum renalase concentration. The questionnaire method of assessing exposure to tobacco smoke was characterized by high sensitivity, but only moderate specificity, especially in terms of assessing environmental exposure to tobacco smoke. In summary, the study showed an independent relationship between exposure to tobacco smoke and lower serum renalase concentration.
Subject(s)
Biomarkers , Cotinine , Hypertension , Monoamine Oxidase , Tobacco Smoke Pollution , Humans , Cotinine/blood , Middle Aged , Tobacco Smoke Pollution/adverse effects , Male , Female , Adult , Biomarkers/blood , Hypertension/diagnosis , Hypertension/blood , Hypertension/epidemiology , Hypertension/physiopathology , Monoamine Oxidase/blood , Surveys and Questionnaires , Smoking/adverse effects , Smoking/blood , Smoking/epidemiology , Aged , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/blood , Cardiovascular Diseases/epidemiology , Smokers , Risk Factors , Risk Assessment , Arterial Pressure , Predictive Value of TestsABSTRACT
Background: E-waste sorting workers usually separate electronic waste. Therefore, they can be exposed to heavy metals. Objectives: This study compared monoamine oxidase (MAO) levels affected by the levels of lead (Pb), cadmium (Cd), and nickel (Ni) in the blood and their workplace among e-waste sorting workers (EWSW). Material and methods: The exposed group included 76 EWSW, and the non-exposed group included 49 village health volunteers. An interview form was used to assess the risk factors. We measured Pb, Cd, and Ni on the work surfaces and in the blood, and MAO levels as a neurological enzymes. Results: Among the EWSW, 42 were males (55.3%), and the mean age (SD) 48.0 (12.64) years, and income were 156.37 ± 88.08 USD. In the work areas of the exposed group, the concentration of Pb, Cd, and Ni were 245.042 (± 613.910), 0.375 (± 0.662), and 46.115 (± 75.740) µg/100 cm2, respectively, while the non-exposed group, the concentration of Pb, Cd, and Ni were 0.609 (± 0.934), 0.167 (± 1.171) and 1.020 (± 0.142) µg/100 cm2. Pb and Ni concentrations in the workplace of the exposed groups were statistically different from that of the non-exposed group. Pb, Cd, and Ni concentrations in serum were 6.411 ± 1.492 µg/dL, 0.9480 ± 0.350 µg/L, 2.568 ± 0.468 µg/L, respectively, while in the non-exposed group, the heavy metal concentrations were 6.411 ± 1.620 µg/dL, 0.909 ± 0.277 µg/L, 2.527 ± 0.457 µg/L. The MAO in the exposed group was 362.060 ± 97.981 U/L, while that in the non-exposed group was 369.771 ± 86.752 U/L. Moreover, MAO concentration was significantly different from Ni concentration (p < 0.05). Conclusion: The electronic waste sorting workers should clean their work areas to reduce the Pb, Cd, and Ni levels on the working surfaces, and health surveillance should be performed.
Subject(s)
Electronic Waste , Metals, Heavy , Monoamine Oxidase , Female , Humans , Male , Middle Aged , Cadmium/blood , Cadmium/chemistry , Electronic Waste/adverse effects , Environmental Monitoring , Lead/blood , Lead/chemistry , Metals, Heavy/blood , Metals, Heavy/chemistry , Monoamine Oxidase/blood , Monoamine Oxidase/chemistry , Nickel/blood , Nickel/chemistry , Thailand/epidemiology , WorkplaceABSTRACT
Renalase is a secreted flavoprotein with anti-inflammatory and pro-cell survival properties. COVID-19 is associated with disordered inflammation and apoptosis. We hypothesized that blood renalase levels would correspond to severe COVID-19 and survival. In this retrospective cohort study, clinicopathologic data and blood samples were collected from hospitalized COVID-19 subjects (March-June 2020) at a single institution tertiary hospital. Plasma renalase and cytokine levels were measured and clinical data abstracted from health records. Of 3,450 COVID-19 patients, 458 patients were enrolled. Patients were excluded if <18 years, or opted out of research. The primary composite outcome was intubation or death within 180 days. Secondary outcomes included mortality alone, intensive care unit admission, use of vasopressors, and CPR. Enrolled patients had mean age 64 years (SD±17), were 53% males, and 48% non-whites. Mean renalase levels was 14,108·4 ng/ml (SD±8,137 ng/ml). Compared to patients with high renalase, those with low renalase (< 8,922 ng/ml) were more likely to present with hypoxia, increased ICU admission (54% vs. 33%, p < 0.001), and cardiopulmonary resuscitation (10% vs. 4%, p = 0·023). In Cox proportional hazard model, every 1000 ng/ml increase in renalase decreased the risk of death or intubation by 5% (HR 0·95; 95% CI 0·91-0·98) and increased survival alone by 6% (HR 0·95; CI 0·90-0·98), after adjusting for socio-demographics, initial disease severity, comorbidities and inflammation. Patients with high renalase-low IL-6 levels had the best survival compared to other groups (p = 0·04). Renalase was independently associated with reduced intubation and mortality in hospitalized COVID-19 patients. Future studies should assess the pathophysiological relevance of renalase in COVID-19 disease.
Subject(s)
COVID-19/pathology , Monoamine Oxidase/blood , Adult , Aged , COVID-19/mortality , COVID-19/virology , Endothelium/metabolism , Endothelium/pathology , Female , Hospitalization , Humans , Intensive Care Units , Interleukin-6/blood , Kaplan-Meier Estimate , Male , Middle Aged , Proportional Hazards Models , Respiration, Artificial , Retrospective Studies , Risk Factors , SARS-CoV-2/isolation & purification , Severity of Illness IndexABSTRACT
BACKGROUND: Renalase is an enzyme and a cytokine involved in cell survival. Since its discovery, associations between it and both cardiovascular and kidney disease have been noted. Recognizing this, we conducted a study in which we followed patients with chronic kidney disease. MATERIAL AND METHODS: The study involved 90 CKD patients with varying stages of the disease and 30 healthy controls. Renalase was measured with an ELISA kit, and patients were followed-up after a median of 18 months. During the follow-up, we asked about the occurrence of MACE, all-cause mortality and the need for dialysis initiation. RESULTS: In CKD subgroups, RNSL correlated with all-cause death only in the HD group (Rs = 0.49, p < 0.01). In the whole CKD population, we found a positive correlation of RNSL concentration and both MACE occurrence (Rs = 0.38, p < 0.001) and all-cause death (Rs = 0.34, p < 0.005). There was a significant increase in MACE occurrence probability in patients with elevated renalase levels (>25 µg/mL). CONCLUSIONS: Elevated renalase levels can be used as a risk factor of MACE in patients with CKD, but its long-term utility needs further research. High renalase levels are a risk factor of death among CKD patients. In HD patients, all deaths were observed among patients with >30 µg/mL; this level could be used as a "red flag" marker in future studies.
Subject(s)
Cardiovascular Diseases/blood , Monoamine Oxidase/blood , Renal Insufficiency, Chronic/blood , Adult , Aged , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Cardiovascular Diseases/pathology , Cause of Death , Female , Heart Disease Risk Factors , Humans , Male , Middle Aged , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/mortality , Renal Insufficiency, Chronic/pathologyABSTRACT
Dysregulated expression of the secretory protein renalase can promote pancreatic ductal adenocarcinoma (PDAC) growth in animal models. We characterized renalase expression in premalignant and malignant PDAC tissue and investigated whether plasma renalase levels corresponded to clinical PDAC characteristics. Renalase immunohistochemistry was used to determine the presence and distribution of renalase in normal pancreas, chronic pancreatitis, PDAC precursor lesions, and PDAC tissues. Associations between pretreatment plasma renalase and PDAC clinical status were assessed in patients with varied clinical stages of PDAC and included tumor characteristics, surgical resection in locally advanced/borderline resectable PDAC, and overall survival. Data were retrospectively obtained and correlated using non-parametric analysis. Little to no renalase was detected by histochemistry in the normal pancreatic head in the absence of abdominal trauma. In chronic pancreatitis, renalase immunoreactivity localized to peri-acinar spindle-shaped cells in some samples. It was also widely present in PDAC precursor lesions and PDAC tissue. Among 240 patients with PDAC, elevated plasma renalase levels were associated with worse tumor characteristics, including greater angiolymphatic invasion (80.0% vs. 58.1%, p = 0.012) and greater node positive disease (76.5% vs. 56.5%, p = 0.024). Overall survival was worse in patients with high plasma renalase levels with median follow-up of 27.70 months vs. 65.03 months (p < 0.001). Renalase levels also predicted whether patients with locally advanced/borderline resectable PDAC underwent resection (AUC 0.674; 95%CI 0.42-0.82, p = 0.04). Overall tissue renalase was increased in both premalignant and malignant PDAC tissues compared to normal pancreas. Elevated plasma renalase levels were associated with advanced tumor characteristics, decreased overall survival, and reduced resectability in patients with locally advanced/borderline resectable PDAC. These studies show that renalase levels are increased in premalignant pancreatic tissues and that its levels in plasma correspond to the clinical behavior of PDAC.
Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Pancreatic Ductal/pathology , Monoamine Oxidase/blood , Pancreatic Neoplasms/pathology , Up-Regulation , Adult , Aged , Aged, 80 and over , Carcinoma, Pancreatic Ductal/blood , Carcinoma, Pancreatic Ductal/mortality , Case-Control Studies , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Neoplasm Grading , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/mortality , Prognosis , Prospective Studies , Retrospective Studies , Survival Analysis , Young Adult , Pancreatic NeoplasmsABSTRACT
The review summarizes the results of our own studies and published data on the biological markers of psychiatric disorders, with special emphasis on the activity of platelet monoamine oxidase. Pharmacotherapy studies in patients with the mixed anxiety-depressive disorder and first episode of schizophrenia have shown that the activity of platelet monoamine oxidase could serve as a potential biomarker of the efficacy of therapeutic interventions in these diseases.
Subject(s)
Blood Platelets/enzymology , Mental Disorders/blood , Monoamine Oxidase/blood , Depressive Disorder/blood , Depressive Disorder/drug therapy , Humans , Mental Disorders/drug therapy , Schizophrenia/blood , Schizophrenia/drug therapy , Treatment OutcomeABSTRACT
As enzymes in the outer membrane of the mitochondrion, monoamine oxidases (MAOs) can catalyze the oxidative deamination of monoamines in the human body. According to different substrates, MAOs can be divided into MAO-A and MAO-B. The imbalance of the MAO-A is associated with neurological degeneration, while excess MAO-B activity is closely connected with Parkinson's disease (PD) and Alzheimer's disease (AD); therefore, detection of MAOs is of great significance for the diagnosis and treatment of these diseases. This work reports the multiplexed detection of MAO-A and MAO-B using paper-based devices based on chemiluminescence (CL). The detection limits were 5.01 pg/mL for MAO-A and 8.50 pg/mL for MAO-B in human serum. In addition, we used paper-based devices to detect MAOs in human cells and tissue samples and found that the results of paper-based detection and Western blotting (WB) showed the same trend. While only one antibody can be incubated on the same membrane by WB, multiple antibodies incubated on the same paper enabled simultaneous detection of MAO-A and MAO-B by paper-based devices. The paper-based assay could be used for preliminary early screening of clinical samples for MAOs and can be extended as an alternative to WB for multiplexed detection of various proteins in disease cell or tissue samples.
Subject(s)
Equipment and Supplies , Monoamine Oxidase/blood , Monoamine Oxidase/metabolism , Paper , Cell Line , Humans , Neoplasms/enzymology , Neoplasms/metabolismABSTRACT
BACKGROUND: Renalase plays an important role in blood pressure regulation. Obstructive sleep apnea (OSA) is a common respiratory disorder associated with hypertension and cardiovascular complications. The aim of the study was to assess the relationship between sleep apnea and renalase concentration. MATERIAL AND METHODS: Adult patients (n = 113) were evaluated for OSA in a sleep laboratory using polysomnography. The respiratory events were scored according to the standards developed by the American Academy of Sleep Medicine. The blood renalase concentration was determined by the ELISA (enzyme-linked immunosorbent assay) test. RESULTS: OSA (AHI ≥ 5) was diagnosed in 71% (n = 80) of the studied population. Renalase concentration was statistically significantly lower in the group with moderate-to-severe OSA (AHI ≥ 15) compared with the group without OSA (AHI < 5) (139.56 ± 175.72 ng/ml vs. 230.97 ± 240.50 ng/ml, p = 0.042). We have found statistically significant negative correlation between renalase and AHI in hypertensives, but not in normotensives. The statistically significant negative correlation was observed between AHI and renalase in the whole studied group, in males, and in the group of age < 60 years old. There was not such a correlation in females and in the group > 60 years old. Based on the regression model, it was shown that lower renalase concentration, hypertension, higher BMI, and male gender are independently associated with higher AHI. CONCLUSIONS: There is a relationship between the blood renalase concentration and the severity of OSA, which may influence hypertension development in OSA.
Subject(s)
Hypertension/physiopathology , Monoamine Oxidase/blood , Sleep Apnea, Obstructive/blood , Sleep Apnea, Obstructive/epidemiology , Adult , Demography , Female , Humans , Hypertension/epidemiology , Male , Middle Aged , Polysomnography , Risk FactorsABSTRACT
Juvenile delinquency is related to several biological factors, yet very few vulnerability biomarkers have been identified. Previous data suggest that the enzyme monoamine oxidase B (MAO-B) influences several personality traits linked to the propensity to engage in delinquent behavior. Building on this evidence, we assessed whether conduct disorder (CD), juvenile delinquency adjudications, or detention in a correctional facility were associated with either platelet MAO-B activity or the MAOB rs1799836 polymorphism. The study enrolled 289 medication-free male youths, including 182 individuals detained in a correctional facility (with or without a diagnosis of CD). Of the remaining 107 participants, 26 subjects had a diagnosis of CD, and 81 were mentally healthy controls. Platelet MAO-B activity was determined by spectrophotofluorometry, while MAOB rs1799836 was genotyped using qPCR. Platelet MAO-B activity, corrected for age and smoking, was significantly higher in juvenile detainees (p < 0.001), irrespective of CD diagnosis. MAOB rs1799836 was not associated with platelet MAO-B activity or with detention in a correctional facility, CD diagnosis, or delinquent behavior. These data suggest that detention in a juvenile correctional facility increases platelet MAO-B activity in male adolescents. Future studies are needed to determine the mechanisms and functional significance of MAO-B peripheral elevation in juvenile male detainees.
Subject(s)
Blood Platelets/metabolism , Correctional Facilities/trends , Juvenile Delinquency/trends , Monoamine Oxidase/blood , Polymorphism, Genetic/physiology , Adolescent , Croatia/epidemiology , Humans , Juvenile Delinquency/psychology , Male , Monoamine Oxidase/geneticsABSTRACT
The study describes two approaches to enhance oxidoreductases. Both target molecular "wiring" of enzymes using green processes. The concepts were tested on plasma amine oxidase (PAO). In the first procedure PAO was transiently exposed to an ionic liquid (IL) in the presence of redox molecules, which resulted in partial unfolding. During subsequent dialysis, the enzyme refolded entrapping redox units and affording shorter distances for electron tunneling, hence a molecular "wire" to PAO's prosthetic groups. The other procedure described herein was totally reagentless, using high hydraulic pressure (HHP) to partially denature PAO (in the presence of redox molecules) followed by dialysis and refolding. The two approaches to enzyme "wiring" are discussed comparatively from the point of view of the parameters used during the procedure, residual enzyme activity, nature of the modifier, interaction between PAO and the redox molecules, and stability over time. The most active modified PAO (PAO-ME) from each series was tested in a biosensor for amine detection, toward applications in the food industry and clinical laboratory. Our approaches used "green" reagents (IL) and were made enzyme-friendly as well by the choice of "wires".
Subject(s)
Green Chemistry Technology/methods , Monoamine Oxidase/blood , Antioxidants/metabolism , Benzylamines/chemistry , Biosensing Techniques , Copper/chemistry , Electrochemistry , Freeze Drying , Ionic Liquids/chemistry , Monoamine Oxidase/chemistry , Pressure , Spectroscopy, Fourier Transform InfraredABSTRACT
Urinary biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and renalase were recently studied for their potential role in the early detection of acute kidney injury (AKI) in patients with cirrhosis. Our study was conducted on 50 patients with end-stage liver disease undergoing living donor liver transplantation. The patients were divided into two groups: Group I contained 23 patients with AKI who had undergone liver transplantation and Group II included 27 non-AKI patients who had undergone liver transplantation. Serum renalase and NGAL levels were measured by ELISA; renalase was measured on day 1, day 7, and three months after liver transplantation. NGAL was measured on day 1 postliver transplantation. There was an improvement in liver function, kidney functions, hemoglobin level, platelet count, and C- reactive protein levels in patients at three months posttransplantation when compared to day 1, day 3, and day 7 (P < 0.01). Comparison of the renalase level at day 1, day 7, and three months showed that there was a highly significant decline at three months in the AKI group compared to the non-AKI group (P < 0.01). Regarding the NGAL level at day 1, there was no significant difference between the AKI and non-AKI groups (P > 0.05). The receiver operating characteristic curve for the renalase biomarker showed a borderline significant change between the AKI and non-AKI groups at day 1 [area under the curve (AUC): 0.54, P = 0.08], day 7 (AUC: 0.605, P = 0.08), and three months (AUC: 0.605, P = 0.08). However, the NGAL biomarker level was not significantly different between the AKI and non-AKI groups. Our study suggests that renalase showed a better predictive value and a higher accuracy in identifying postliver transplantation patients with AKI than NGAL.
Subject(s)
Acute Kidney Injury/blood , End Stage Liver Disease/surgery , Lipocalin-2/blood , Liver Transplantation/adverse effects , Living Donors , Monoamine Oxidase/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/etiology , Adult , Biomarkers , End Stage Liver Disease/diagnosis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Time Factors , Treatment Outcome , Young AdultABSTRACT
Septic shock is associated with a strong inflammatory response that induces vasodilation and vascular hyporeactivity. We investigated the role for tryptophan-pathway catabolites of proinflammatory cytokines in septic shock.We prospectively included 30 patients with very recent-onset septic shock and 30 healthy volunteers. The following were assayed once in the controls and on days 1, 2, 3, 7, and 14 in each patient: plasma free and total tryptophan, platelet and plasma serotonin, total blood serotonin, urinary serotonin, plasma and urinary 5-hydroxyindolacetic acid, plasma kynurenine, monoamine oxidase activity, and total indole amine 2,3-dioxygenase activity. Organ-system failure and mortality were recorded.Compared with the healthy controls, the patients with septic shock had 2-fold to 3-fold lower total tryptophan levels throughout the 14-day study period. Platelet serotonin was substantially lower, while monoamine oxidase activity and 5-hydroxyindolacetic acid were markedly higher in the patients than in the controls, consistent with the known conversion of tryptophan to serotonin, which is then promptly and largely degraded to 5-hydroxyindolacetic acid. Plasma kynurenine was moderately increased and indole amine 2,3-dioxygenase activity markedly increased in the patients versus the volunteers, reflecting conversion of tryptophan to kynurenine. Changes over time in tryptophan metabolites were not associated with survival in the patients but were associated with the Sequential Organ Failure Assessment score and hemodynamic variables including hypotension and norepinephrine requirements.Our results demonstrate major tryptophan pathway alterations in septic shock. Marked alterations were found compared with healthy volunteers, and tryptophan metabolite levels were associated with organ failure and hemodynamic alterations. Tryptophan metabolite levels were not associated with surviving septic shock, although this result might be ascribable to the small sample size.Trial registration: ClinicalTrials.gov; No: NCT00684736; URL: www.clinicaltrials.gov.
Subject(s)
Shock, Septic/blood , Shock, Septic/mortality , Tryptophan/blood , Aged , Case-Control Studies , Female , Humans , Hydroxyindoleacetic Acid/blood , Indoleamine-Pyrrole 2,3,-Dioxygenase/blood , Kynurenine/blood , Male , Middle Aged , Monoamine Oxidase/blood , Organ Dysfunction Scores , Prospective Studies , Serotonin/blood , Survival RateABSTRACT
Objective: Heart failure (HF) represents a huge socio-economic burden. It has been demonstrated, experimentally, that renalase, a newly discovered protein, prevents cardiac hypertrophy and adverse remodeling, which is seen in HF. We postulated the following aims: to investigate associations of renalase with biomarkers of cardiac remodeling: galectin-3, soluble suppression of tumorigenicity, (sST2), growth differentiation factor 15 (GDF-15) and syndecan-1, myocardial stretch (BNP) and cardio-renal axis (cystatin C) in HF patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) to determine whether renalase, in combination with left ventricular ejection fraction (LVEF), represents a risk factor for plasma elevation in biomarkers.Methods: We classified HF patients (n = 76) according to LVEF (preserved/reduced), applied a median plasma renalase (113 ng/mL) as a cut-off value (low/high) and created four subgroups of HF patients: HFpEF/low renalase (n = 19), HFrEF/low renalase (n = 19), HFrEF/high renalase (n = 32) and HFpEF/high renalase (n = 6). A control group (n = 35) consisted of healthy volunteers.Results: Plasma concentrations of evaluated biomarkers were determined using an ELISA technique and were highest in HF patients with reduced EF (p < .001, respectively), and renalase's positive correlations were obtained relating to all biomarkers: galectin-3 (r = 0.913; p < .001), sST2 (r = 0.965; p < .001), GDF-15 (r = 0.887; p < .001), syndecan-1 (r = 0.922; p < .001), BNP (r = 0.527; p < .001) and cystatin C (r = 0.844; p < .001) and strong and negative correlation with LVEF (r = -0.456, p < .001). Increased renalase, regardless of the EF (preserved/reduced), was shown to be an independent risk factor for an increase in all evaluated cardiac remodeling biomarkers, p < .001, respectively. However, increased renalase and reduced EF was the only independent risk factor for BNP and cystatin C elevation, p < .001, respectively. Results after multivariable adjustments (age/gender) were identical.Conclusion: When elevated plasma renalase and HF are present, regardless of EF being reduced or preserved, that represents a significant risk factor for increase in cardiac remodeling biomarker plasma concentrations. However, only elevated renalase and reduced EF demonstrated significance as a risk factor for BNP and cystatin C plasma elevation. Renalase may be considered a promising molecule for the improved predictive abilities of conventional biomarkers and is worthy of further investigation.
Subject(s)
Heart Failure/physiopathology , Monoamine Oxidase/blood , Stroke Volume/physiology , Ventricular Remodeling/physiology , Aged , Biomarkers/blood , Chronic Disease , Female , Growth Differentiation Factor 15/blood , Heart Failure/enzymology , Humans , Male , Middle Aged , Risk Factors , Ventricular Function, LeftABSTRACT
BACKGROUND: Renalase is a flavoprotein that plays a protective role in chronic kidney disease (CKD) and cardiovascular diseases. The secretion and way of action of this protein are still discussed. The aim of our study was to estimate the balance between serum and urine renalase in healthy individuals and CKD patients, using two parameters: fractional excretion (FE) and serum-to-urine renalase ratio (StURR). METHODS: Our study involved 28 healthy volunteers and 62 patients with CKD in stages I to IV. The concentration of renalase in serum and urine was measured using an enzyme-linked immunosorbent assay (ELISA) kit (EIAab, Wuhan, China). We analyzed associations between renalase levels in urine and serum, and other parameters: sex, age, GFR, presence of hypertension, diabetes, and proteinuria, and determined the serum-to-urine renalase ratio and fractional excretion of renalase. RESULTS: Renalase and serum-to-urine ratio were significantly higher in CKD patients in comparison with the control group. Fractional excretion was lower in CKD patients but this difference did not reach the statistical significance (p = 0.092). Multivariate analysis performed in the CKD group showed, that from mentioned parameters, serum renalase was the only significant independent factor strongly positively associated with urinary renalase concentration. CONCLUSIONS: The serum-to-urine ratio is significantly and about 6.5-fold higher in CKD patients, and the fractional excretion of renalase is 3-fold, but not significantly lower in CKD patients. Renalase levels in both serum and urine are not related to the glomerular filtration rate and not associated with blood pressure.
Subject(s)
Monoamine Oxidase/blood , Monoamine Oxidase/urine , Renal Insufficiency, Chronic/enzymology , Adult , Age Factors , Blood Pressure , Diabetes Complications , Female , Glomerular Filtration Rate , Humans , Hypertension/complications , Male , Middle Aged , Proteinuria/complications , Reference Values , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/physiopathology , Sex FactorsABSTRACT
Earlier, we reported that chronic exposure to pesticides causes a reduction in the acetylcholinesterase activity and hematological and biochemical alterations in agriculture workers. In continuation with that, the present study aimed to investigate the pesticide-induced neurochemical imbalance and its association with behavior alterations in agricultural workers. A significant increase in depressive symptoms, assessed by the Beck Depression Inventory-II was observed in pesticide exposed workers as compared to the unexposed. A decrease in the level of dopamine in plasma and levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acids, norepinephrine, serotonin, and hydroxyindoleacetic acid in urine was also observed. An increase in the levels of MAO-A and MAO-B has also been observed in these individuals. The decreased levels of neurotransmitters in the blood and urine have been linked with increased levels of MAO and pesticide residues in plasma and urine. Furthermore, these changes were associated with a higher incidence of depression in agricultural workers.
Subject(s)
Depression/chemically induced , Farmers , Neurotoxicity Syndromes/etiology , Occupational Exposure , Pesticide Residues/toxicity , Adolescent , Adult , Aged , Biomarkers/blood , Biomarkers/urine , Depression/blood , Depression/epidemiology , Depression/urine , Dopamine/blood , Dopamine/urine , Female , Humans , Incidence , India/epidemiology , Male , Middle Aged , Monoamine Oxidase/blood , Monoamine Oxidase/urine , Neurotoxicity Syndromes/blood , Neurotoxicity Syndromes/epidemiology , Neurotoxicity Syndromes/urine , Neurotransmitter Agents/blood , Neurotransmitter Agents/urine , Pesticide Residues/blood , Pesticide Residues/urine , Young AdultABSTRACT
Renalase is predominantly expressed in the kidney, where it plays a role in catecholamine metabolism and blood pressure regulation. Moderate-intensity exercise (MEX) has been shown to increase the concentration of renalase in the blood and to reduce renal function in humans. Moreover, such exercise was also reported to increase catecholamine levels. Here, we examined renalase concentration in the blood and renalase expression levels in different organs after MEX in rats. Twelve male Wistar rats were made to run on a treadmill (MEX group) for 60 min at 20 m·min-1 , after resting for 15 min. The control group rats were euthanized after resting on the treadmill. Tissue and blood samples were analyzed using western blotting, real-time RT-PCR and ELISA. Overall, the concentrations of renalase in the blood were significantly higher in the MEX group than that in the control group. Renalase expression was decreased in the kidney after 60 min of exercise, whereas the expression of renalase mRNA and protein in the extensor digitorum longus and plantaris muscles, respectively, increased after exercise. However, the expression of renalase in the other tissues examined did not change after acute exercise. In conclusion, we report that MEX for 60 min increases both renalase concentration in the blood and its expression in skeletal muscle.
Subject(s)
Monoamine Oxidase/blood , Muscle, Skeletal/enzymology , Physical Conditioning, Animal , Animals , Blood Pressure , Catecholamines/metabolism , Kidney/enzymology , Male , Models, Animal , Monoamine Oxidase/metabolism , Rats , Rats, WistarABSTRACT
Heart failure represents a growing health problem, with increasing morbidity and mortality globally. According to the mechanisms involved in the pathogenesis of heart failure, many biomarkers have been proposed for the timely diagnosis and prognostication of patients with heart failure, but other than natriuretic peptides, none of them has gained enough clinical significance. Renalase, a new protein derived from kidneys was demonstrated to metabolize catecholamines and to have a cardioprotective role. The aim of the study was to determine whether renalase and brain natriuretic peptide (BNP) concentration could be used to differentiate heart failure patients stratified to the category of the ejection fraction and whether plasma renalase could be used as a biomarker for left ventricle hypertrophy in all subgroups of heart failure patients. We included patients diagnosed with heart failure and stratified them to the three subgroups according to the ejection fraction. Regarding echocardiographic parameters, HFmrEF had an intermediate profile in between HFrEF and HFpEF, with statistical significance in most evaluated parameters. BNP concentration was significantly different in all three subgroups (p < 0.001), and renalase was statistically higher in HFrEF (p = 0.007) compared to the HFmrEF and HFpEF, where its results were similar, without statistical significance. Renalase plasma concentration was demonstrated to be highly and positively associated with left ventricle mass index in HFrEF (p = 0.029), as well as increased plasma concentration of BNP (p = 0.006). In the HFmrEF group of patients, body mass index was positively associated with LVMI (p = 0.05), while in the patients with HFpEF, diabetes mellitus was demonstrated to have a positive association with LVMI (p = 0.043). These findings suggest that renalase concentration may be measured in order to differentiate patients with reduced ejection fraction. Plasma renalase concentrations positively correlated with left ventricle hypertrophy in patients with reduced ejection fraction, being strongly associated with increased left ventricular mass index.
Subject(s)
Biomarkers/blood , Heart Failure/blood , Hypertrophy, Left Ventricular/blood , Monoamine Oxidase/blood , Aged , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Pilot Projects , Ventricular Dysfunction, Left/bloodABSTRACT
INTRODUCTION: Renalase is a novel flavin adenine dinucleotide-dependent amine oxidase with catecholamine-degrading activity. The kidneys are the main source of this enzyme. OBJECTIVES: In this study, we examined the concentrations of renalase in the serum, urine, and erythrocytes of patients with chronic kidney disease (CKD). PATIENTS AND METHODS: We enrolled 155 white patients with CKD and 30 healthy controls. Renalase concentrations were measured using an enzymelinked immunosorbent assay. RESULTS: Serum renalase levels were higher in patients with CKD than in controls: median (Q1-Q3), 103 ng/ml (55.6-166 ng/ml) vs 17.7 ng/ml (16.3-21.8 ng/ml); P <0.001. Renalase levels in erythrocytes were lower in patients with CKD than in controls (median [Q1-Q3], 122 ng/ml [67.2-189 ng/ml] vs 254 ng/ml [166-293 ng/ml]; P <0.001). Urinary renalase levels did not differ between patients with CKD and controls (median [Q1-Q3], 147 ng/ml [102-193 ng/ml] vs 144 ng/ml [116-170 ng/ml]; P = 0.78). Urinary and erythrocyte renalase concentrations were negatively correlated with estimated glomerular filtration rate (eGFR). A multivariate general linear model analysis adjusted for age, sex, and eGFR of CKD patients showed that higher plasma dopamine and total protein concentrations were independent predictors of higher serum renalase levels (ß = 0.32, P <0.001 and ß = 0.25, P <0.001, respectively). CONCLUSIONS: Our results indicate that serum renalase concentrations are elevated in patients with CKD, whereas renalase concentrations in urine and erythrocytes are correlated with impaired kidney function.
Subject(s)
Biomarkers/blood , Biomarkers/urine , Erythrocytes/chemistry , Monoamine Oxidase/blood , Monoamine Oxidase/urine , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/complications , Adult , Aged , Female , Healthy Volunteers , Humans , Male , Middle Aged , Renal Insufficiency, Chronic/physiopathology , White People/statistics & numerical dataABSTRACT
Background: Renalase is kidney-derived molecule initially considered as catecholamine-inactivating enzyme. However, recent studies suggest that renalase exerts potent cardio- and nephroprotective actions, not related to its enzymatic activity. Purpose: To assess renalase level in children with chronic kidney disease (CKD). Material and methods: Serum renalase, BMI, arterial stiffness, peripheral and central blood pressure, intima-media thickness (IMT), medications, and biochemical parameters were analyzed in 38 children with CKD (12.23 ± 4.19 years) (stage G2-5). Control group consisted of 38 healthy children. Results: In the study group, GFR was 25.74 ± 8.94 mL/min/1.73 m2; 6 children were dialyzed; 26 had arterial hypertension. Renalase level was higher in the study group compared to control group (p < 0.001). In CKD children renalase correlated (p < 0.05) with BMI Z-score (r = -0.36), alfacalcidol dose (r = 0.41), GFR (r = -0.69), hemoglobin (r = -0.48), total cholesterol (r = 0.35), LDL-cholesterol (r = 0.36), triglycerides (r = 0.52), phosphate (r = 0.35), calcium-phosphorus product (r = 0.35), parathormone (r = 0.58), and pulse wave velocity Z-score (r = 0.42). In multivariate analysis GFR (ß = -0.63, p < 0.001), triglycerides (ß = 0.59, p = 0.002), and alfacalcidol dose (ß = -0.49, p = 0.010) were determinants of renalase. Conclusions: In children with CKD there is a strong correlation between renalase level and CKD stage. Furthermore, in these patients renalase does not correlate with blood pressure but may be a marker of arterial stiffness.